• News
  • BioTech

BioTheranostics signs contract with FedMed

BioTheranostics Inc., a San Diego-based genomic solutions provider for cancer diagnosis, signed a contract with FedMed Inc., one of the largest preferred provider organization networks in the United States.

The contract will provide FedMed's 40 million members access to bioTheranostics’ genomic tests for patients with breast cancer and metastatic cancers.

BioTheranostics’ molecular diagnostic and predictive cancer tests include the Breast Cancer Index, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, and the bioT3 Metastatic Cancer Solution suite of tests, which provide diagnostic and therapeutic information for metastatic cancer patients at any stage across the continuum of care.

User Response
0 UserComments